8 analysts have shared their evaluations of DexCom (NASDAQ:DXCM) during the recent three months, expressing a mix of bullish and bearish perspectives. The following table encapsulates their recent ...
Supermodels, singers, and diabetics are all wearing it. Jake Leach, Dexcom CEO, says these sensors are the future.
DexCom (NASDAQ:DXCM) underwent analysis by 8 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The table below offers a condensed view of their recent ratings, ...
Robert W. Baird analyst Jeff Johnson reiterated a Buy rating on Dexcom (DXCM – Research Report) on January 8 and set a price target of $161.00. Jeff Johnson has given his Buy rating due to a ...
Bill McColl has 25+ years of experience as a senior producer and writer for TV, radio, and digital media leading teams of anchors, reporters, and editors in creating news broadcasts, covering some of ...
DexCom Q4 revenue beat at $1.114B, up 8% Y/Y, but EPS missed at $0.45 vs. $0.50 consensus. FY25 guidance reaffirmed with $4.6B revenue target and 21% operating margin. Get stock picks, daily rankings, ...
StockStory.org on MSN
DexCom (DXCM) stock trades down, here is why
What Happened? Shares of medical device company DexCom (NASDAQ:DXCM) fell 2.6% in the morning session after analysts at Piper ...
DexCom, incorporated in Delaware and headquartered in San Diego, California, designs, manufactures, and markets continuous glucose monitoring (CGM) systems to help individuals with types 1 and 2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback